Engene reports inducement grants under nasdaq listing rule 5635(c)(4)

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously eg-70), is in an ongoing pivotal study in patients with high-risk, bacillus calmette-guÉrin (bcg)-unresponsive, non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), today reported the grant of inducement equity awards to.
ENGN Ratings Summary
ENGN Quant Ranking